CHTF
6.8.2024 03:01:29 CEST | Business Wire | Press release
The 26th China Hi-tech Fair (CHTF2024) will take place on November 14-16, 2024 in Shenzhen China. This year’s fair promises to be a groundbreaking event, covering approximately 400,000m2 and attracting over 5,000 renowned enterprises and international organizations from more than 100 countries and regions. CHTF2024 will feature multiple exhibition zones covering AI and robotics, clean energy, high-end medical devices, China’s leading heavy equipment, top tech industry chains, etc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802870555/en/
Global Buyer Invitation Programme of the 26th China Hi-tech Fair (CHTF2024) (Graphic: Business Wire)
China has solidified its position as a global technology powerhouse, with significant advancements in AI, big data, 5G, and clean energy. CHTF serves as a vital platform for debuting innovations and facilitating exchanges. In 2024, the ultimate platform invites global powerful exhibitors to win business for innovation in China’s huge tech market.
To ensure the maximum value for exhibitors, buyers, and visitors, CHTF has launched a comprehensive Global Buyer Invitation Programme, which will invite nearly 500 international buyer delegations from Europe, America, Southeast Asia, the Middle East, and other regions. The anticipated 500,000 professional visitors will create an unparalleled opportunity for business growth and networking.
Key Highlights of The Programme:
- International and Domestic Buyer Delegations: The event collaborates with prestigious buyer delegations formed by state-owned enterprises, industry leaders, and international corporations, including PetroChina (CNPC), China National Offshore Oil Corporation (CNOOC), CIPR-The conference “Digitalization of Industrial Russia”, Australian Trade & Investment Commission, etc.
- Tailored Matchmaking: Customized procurement matchmaking events and industry-specific conferences will be held to cater to the precise needs of domestic and international buyers.
- Extensive Buyer Outreach: The organizer will collect the specific procurement requirements of high-quality buyers in advance and meticulously select qualified exhibitors to ensure that the matchmaking process is precise and effective.
- Exclusive Buyer Benefits: The registered purchasers can enjoy a range of perks, including VIP privileges, streamlined entry, pre-arranged meetings with exhibitors, complimentary gifts and meals, transportation, and hotel accommodations, and additionally, a chance of lucky draw for signing contracts on-site. (Buyer benefits are subject to change without notice. Please consult the organizer for details.)
With unwavering Shenzhen government backing, extensive industry support, and proven track records of success, CHTF2024 is poised to be the premier destination to explore cutting-edge technologies, foster business collaborations, and contribute to the future of global industries.
Exhibitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/exhibit-apply.html?EID=E0000000413&target=4&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Visitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/vistor-register.html?EID=E0000000413&target=1&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Follow us on Facebook/LinkedIn/X for updates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802870555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release
Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release
Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 13:30:00 CEST | Press release
Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed. Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® meth
Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 12:00:00 CEST | Press release
Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTSGross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom